Valuation : Nuo Therapeutics Inc

Market Cap 60.54M 52.07M 49.13M 44.75M 83.66M 5.79B 84.42M 585M 225M 2.94B 227M 222M 9.33B P/E 2024
-27.4x
P/E 2025 -37.1x
Enterprise Value 60.59M 52.11M 49.17M 44.79M 83.73M 5.79B 84.49M 586M 225M 2.94B 228M 223M 9.33B EV / Sales 2024
47,922,901x
EV / Sales 2025 28,658,774x
Free-Float
42.11%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 63 08/01/2016
Chief Operating Officer 60 30/03/2014
Director TitleAgeSince
Director/Board Member 69 30/01/2009
Chairman 63 07/02/2012
Director/Board Member 67 05/05/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-1.36%+44.08%+102.76% 68.52B
-1.09%-6.20%+30.50%+76.56% 62.88B
-1.18%+0.47%-12.78%+384.69% 28.13B
-1.01%-4.47%+30.50%+10.02% 25.56B
-1.76%-6.30%-4.55%-19.75% 24.65B
-2.39%-5.19%+17.75%-20.95% 19.81B
-1.86%-2.22%+202.03%+353.89% 17.69B
-1.85%-5.07%-5.42%+494.88% 14.66B
-1.54%-2.88%+52.33%+159.75% 14.45B
Average -1.47%-2.00%+39.38%+171.32% 30.71B
Weighted average by Cap. -1.17%-2.18%+35.64%+136.98%

Financials

2024 2025
Net sales 1.37 1.17 1.11 1.01 1.89 130.52 1.9 13.19 5.08 66.2 5.13 5.01 210.28 3.31 2.85 2.69 2.45 4.58 316.8 4.62 32.02 12.32 160.68 12.44 12.17 510.38
Net income -2.32M -2M -1.89M -1.72M -3.21M -222M -3.24M -22.46M -8.64M -113M -8.73M -8.54M -358M -2.51M -2.16M -2.04M -1.86M -3.47M -240M -3.5M -24.28M -9.34M -122M -9.43M -9.23M -387M
Net Debt -120K -103K -96.97K -88.34K -165K -11.43M -167K -1.15M -444K -5.8M -449K -439K -18.41M 48.4K 41.62K 39.27K 35.78K 66.88K 4.63M 67.49K 468K 180K 2.35M 182K 178K 7.46M
Logo Nuo Therapeutics Inc
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. It has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!